Jürg Böni
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013; 208:1102-12.
Jul 11, 2013Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
Jul 11, 2013J Infect Dis 2013; 208:1102-12
Metzner Karin J, Aubert Vincent, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Weber Rainer, Günthard Huldrych F, Klimkait Thomas, Yerly Sabine, Böni Jürg, Scherrer Alexandra U, Preiswerk Benjamin, Joos Beda, von Wyl Viktor, Leemann Christine, Rieder Philip, Braun Dominique, Grube Christina, Kuster Herbert, Swiss HIV Cohort Study
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PloS one 2012; 7:e50307.
Nov 26, 2012Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Nov 26, 2012PloS one 2012; 7:e50307
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, Swiss HIV Cohort Study (SHCS)
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellerai C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS one 2012; 7:e37983.
Jun 18, 2012Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Jun 18, 2012PloS one 2012; 7:e37983
Scherrer Alexandra U, Günthard Huldrych F, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Cellerai Cristina, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations
von Wyl V, Günthard H, Ledergerber B, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Cellerai C, Shah C, Böni J, Yerly S, Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 2011; 54:131-40.
Nov 4, 2011Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations
Nov 4, 2011Clin Infect Dis 2011; 54:131-40
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Vernazza Pietro, Hirschel Bernard, Furrer Hansjakob, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Klimkait Thomas, Cellerai Cristina, Shah Cyril, Böni Jürg, Yerly Sabine, Swiss HIV Cohort Study
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011; 53:1143-52.
Oct 13, 2011Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
Oct 13, 2011Clin Infect Dis 2011; 53:1143-52
Scherrer Alexandra U, Günthard Huldrych F, Held Leonhard, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Hirschel Bernard, Rauch Andri, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland
von Wyl V, Günthard H, Bonhoeffer S, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Staehelin C, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Böni J, Yerly S, Kouyos R, Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 2011; 204:1095-103.
Oct 1, 2011The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland
Oct 1, 2011J Infect Dis 2011; 204:1095-103
von Wyl Viktor, Günthard Huldrych F, Bonhoeffer Sebastian, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Staehelin Cornelia, Cavassini Matthias, Hirschel Bernard, Weber Rainer, Klimkait Thomas, Bürgisser Philippe, Shah Cyril, Böni Jürg, Yerly Sabine, Kouyos Roger D, Swiss HIV Cohort Study
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011; 57:24-31.
May 1, 2011Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
May 1, 2011J Acquir Immune Defic Syndr 2011; 57:24-31
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Cavassini Matthias, Hirschel Bernard, Garzoni Christian, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Swiss HIV Cohort Study (SHCS)
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. J Transl Med 2011; 9:14.
Jan 21, 2011Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
Jan 21, 2011J Transl Med 2011; 9:14
Fehr Jan, Hirschel Bernard, Vernazza Pietro, Martinetti Gladys, Bernasconi Enos, Günthard Huldrych F, Battegay Manuel, Bucher Heiner C, Klimkait Thomas, Fux Christoph A, Cavassini Matthias, Glass Tracy R, Louvel Severine, Hamy Francois, Hirsch Hans H, von Wyl Viktor, Böni Jürg, Yerly Sabine, Bürgisser Philippe, Hiv Cohort Study And The Swiss
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection
Kouyos R, Cavassini M, Rauch A, Battegay M, Vernazza P, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard H, Hirschel B, Weber R, Klimkait T, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011; 52:532-9.
Jan 10, 2011Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection
Jan 10, 2011Clin Infect Dis 2011; 52:532-9
Kouyos Roger D, Cavassini Matthias, Rauch Andri, Battegay Manuel, Vernazza Pietro, Bernasconi Enos, Ledergerber Bruno, Bonhoeffer Sebastian, Günthard Huldrych F, Hirschel Bernard, Weber Rainer, Klimkait Thomas, von Wyl Viktor, Yerly Sabine, Böni Jürg, Rieder Philip, Joos Beda, Taffé Patrick, Shah Cyril, Bürgisser Philippe, Swiss HIV Cohort Study
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load
Alizon S, Bonhoeffer S, Günthard H, Telenti A, Bürgisser P, Battegay M, Bernasconi E, Vernazza P, Rauch A, Furrer H, Klimkait T, Shah C, Böni J, Hirschel B, Yerly S, Kouyos R, Stadler T, von Wyl V, Swiss HIV Cohort Study. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 2010; 6
Sep 30, 2010Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load
Sep 30, 2010PLoS Pathog 2010; 6
Alizon Samuel, Bonhoeffer Sebastian, Günthard Huldrych F, Telenti Amalio, Bürgisser Philippe, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Rauch Andri, Furrer Hansjakob, Klimkait Thomas, Shah Cyril, Böni Jürg, Hirschel Bernard, Yerly Sabine, Kouyos Roger D, Stadler Tanja, von Wyl Viktor, Swiss HIV Cohort Study
Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland
Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 2010; 201:1488-97.
May 15, 2010Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland
May 15, 2010J Infect Dis 2010; 201:1488-97
Kouyos Roger D, Bonhoeffer Sebastian, Ledergerber Bruno, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Furrer Hansjakob, Cavassini Matthias, Hirschel Bernard, Weber Rainer, Klimkait Thomas, Bürgisser Philippe, Shah Cyril, Taffé Patrick, Böni Jürg, Yerly Sabine, von Wyl Viktor, Günthard Huldrych F
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 46:1299-309.
Apr 15, 2008Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
Apr 15, 2008Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 46:1299-309
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Rickenbach Martin, Vernazza Pietro, Hirschel Bernard, Furrer Hansjakob, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Klimkait Thomas, Bürgisser Philippe, Böni Jürg, Yerly Sabine, Swiss HIV Cohort Study
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine 2007; 167:1782-90.
Sep 10, 2007Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
Sep 10, 2007Archives of internal medicine 2007; 167:1782-90
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Perrin Luc, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Hirschel Bernard, Telenti Amalio, Furrer Hansjakob, Battegay Manuel, Klimkait Thomas, Bürgisser Philippe, Böni Jürg, Yerly Sabine, for the Swiss HIV Cohort Study
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6.
Nov 1, 2005HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Nov 1, 2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6
Schüpbach Jörg, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Furrer Hansjakob, Battegay Manuel, Perrin Luc, Yerly Sabine, Tomasik Zuzana, Böni Jürg, Fischer Marek, Joos Beda, Günthard Huldrych, Swiss HIV Cohort Study